Clinical Trials
33 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT00482755 2024-02-12
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Canadian Cancer Trials Group
Phase 2 Completed
NCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
NCT00656669 2023-05-23
Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer
Indiana University
Phase NA Completed
NCT00270413 2022-11-22
SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT00905021 2020-07-24
EXTENT
Baylor Breast Care Center
Phase 1/2 Terminated
NCT00616122 2020-01-13
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
University of California, San Francisco
Phase 1/2 Terminated
NCT00513695 2019-08-07
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
University of Washington
Phase 2 Completed
NCT00428220 2019-06-27
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Pfizer
Phase NA Completed
NCT00824538 2018-04-05
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
University of California, San Francisco
Phase 2 Terminated
NCT02074878 2017-08-09
CRIZENT
Baylor Breast Care Center
Phase 1 Terminated
NCT00887575 2016-09-07
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT01176799 2016-06-22
Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor
National University Hospital, Singapore
Phase 2 Unknown
NCT01803503 2016-06-22
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors
National University Hospital, Singapore
Phase 2 Unknown
NCT02790580 2016-06-06
Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients
National University Hospital, Singapore
Phase 2 Unknown
NCT00570908 2014-09-18
Brain Mets - Capecitabine Plus Sunitinib and WBRT
Baylor Breast Care Center
Phase 2 Terminated
NCT00931450 2013-08-12
Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00662025 2013-05-27
Study Of Sunitinib With Capecitabine In Breast Cancer
Pfizer
Phase 2 Completed
NCT00372424 2012-12-28
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive
Pfizer
Phase 1 Completed
NCT00373256 2012-09-10
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
Pfizer
Phase 3 Completed
NCT00393939 2012-07-19
SUN 1064
Pfizer
Phase 3 Completed
NCT00246571 2012-07-12
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
Pfizer
Phase 2 Completed
NCT00435409 2012-06-26
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer
Pfizer
Phase 3 Completed
NCT00373113 2012-06-25
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
Pfizer
Phase 3 Terminated
NCT00471276 2011-07-25
Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer
Pfizer
Phase 2 Completed
NCT00243503 2011-07-22
Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer
Pfizer
Phase 2 Completed
NCT00417885 2010-09-21
A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
Pfizer
Phase 1/2 Terminated
NCT00618124 2010-05-03
A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together
Pfizer
Phase 1 Completed
NCT00291577 2009-12-23
Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer
Pfizer
Phase 1 Completed
NCT00434356 2009-12-03
A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)
Genentech, Inc.
Phase 2 Terminated
NCT00174434 2009-01-27
Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer
Pfizer
Phase 1 Completed
NCT00078000 2008-11-26
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.
Pfizer
Phase 2 Completed